Skip to main content

Approval in India for Bactiguard

Pressmeddelande   •   Jul 08, 2013 17:03 CEST

 The most important step in achieving regulatory approval for Bactiguard’s BIP Foley catheters on the Indian market has been accomplished. The Medical Device Advisory Committee has reviewed the Bactiguard file and recommended approval of BIP Foley catheters in India.   CEO of Bactiguard, Christian Kinch: ” This approval is a milestone for Bactiguard and we are looking forward to be able to improve patient safety in Indian hospitals. Health care associated infections is a global problem and the fourth largest cause of death in the western world and the numbers are rising in India”.  Bactiguard is present in 25 countries and is represented in over 85 procent of the American hospitals.  The company Bactiguard has the vision of becoming the world leader in reducing all device related health care associated infections. Through innovative technology and techniques,Bactiguard is providing a clinically proven, practical and cost effective solution. The proof of Bactiguard® – over 100.000 patients in clinical studies, 125 million patients. The product Bactiguard® consists of an extremely thin noble metal alloy, with antimicrobial and biocompatible properties. The unique physical and chemical properties of the Bactiguard® coating makes it applicable on any medical device.  

Bactiguard är ett snabbt växande svenskt medicinteknikföretag, som tillverkar och exporterar ett patenterat ytskikt för infektionskänsliga produkter. Bactiguard®-behandlade urinvägskatetrar är marknadsledare i USA och Japan, länder med stora krav på sin sjukvård. Bactiguard har de senaste åren expanderat sin verksamhet till nya marknader, såsom EU, Kina och Mellan Östern, med ett starkt fokus på forskning och utveckling. Bactiguards portfölj omfattar dels BIP CIP – ett koncept för infektionskontroll samt katetrar belagda med Bactiguard®-ytan för urin-, luft och blodvägar.